HUMAN LEUKOCYTE ANTIGEN COMPATIBILITY IN HEART TRANSPLANTATION
- 1 May 1997
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Transplantation
- Vol. 63 (9) , 1346-1351
- https://doi.org/10.1097/00007890-199705150-00024
Abstract
Studies of the influence of human leukocyte antigen (HLA) matching on cardiac transplant outcome have proved inconclusive, mainly due to the lack of well-matched grafts. However, a growing number of studies report improved clinical course and patient survival in cases with increased HLA compatibility. Opelz et al. believe these benefits justify the introduction of prospective HLA-matching strategies. We performed univariate and multivariate analyses to examine the short- and medium-term influence of HLA matching on 556 consecutive primary heart transplants performed at a single center between 1983 and 1994. Overall graft survival at 1, 3, and 5 years was 80%, 74%, and 67% respectively. Sixteen (2.9%) grafts failed within 5 days and were not considered in the analysis of the HLA matching and graft survival data. Complete HLA-A, -B, and -DR typing data were available on 477 transplant pairs. The results demonstrate a 12% 1-year survival advantage for 31 patients with zero to two HLA antigen mismatches compared with three to six mismatches. The influence of each individual locus was 6.1%, 8.4%, and 5.4% for zero HLA-A, -B, and -DR mismatches, respectively, compared with two mismatches. However, when outcome from 1 to 5 years was considered, analysis of the role of each locus revealed marked differences. HLAA-matched grafts (n=45) had a 24% lower survival rate compared with two-antigen-mismatched grafts (n=148; 88% [SE 3.1] vs. 64% [SE 8.2], respectively; P=0.009). Furthermore, 34% of HLA-A-matched grafts failed between 1 and 5 years, compared with only 5% of HLA-B-matched grafts (P=0.013). These data suggest that although HLA matching is effective at reducing acute graft loss, in the longer term, HLA-A matching may impair survival. HLA-A may serve as a restriction element for indirect presentation of allopeptides or tissue-specific minor histocompatibility antigens, facilitating chronic graft loss. Therefore, we advocate a differential role for HLA matching over two epochs. A blanket approach to prospective matching for heart transplants may be premature for optimal long-term survival.Keywords
This publication has 24 references indexed in Scilit:
- IMPORTANCE OF MINIMIZING HLA-DR MISMATCH AND COLD PRESERVATION TIME IN CADAVERIC RENAL TRANSPLANTATIONTransplantation, 1996
- The laws of transplantation: A modern perspectiveEye, 1995
- Indirect presentation of MHC antigens in transplantationImmunology Today, 1994
- MEDIATION OF ACUTE BUT NOT CHRONIC REJECTION OF MHC-INCOMPATIBLE RAT KIDNEY GRAFTS BY ALLOREACTIVE CD4 T CELLS ACTIVATED BY THE DIRECT PATHWAY OF SENSITIZATIONTransplantation, 1993
- Survival of Nationally Shared, HLA-Matched Kidney Transplants from Cadaveric DonorsNew England Journal of Medicine, 1992
- Rejection of skin allografts by indirect allorecognition of donor class I major histocompatibility complex peptides.The Journal of Experimental Medicine, 1992
- THE EFFECT OF HLA MATCHING ON KIDNEY GRAFT SURVIVAL IN SEPARATE POSTTRANSPLANTATION INTERVALSTransplantation, 1990
- EVIDENCE THAT MATCHING FOR HLA ANTIGENS SIGNIFICANTLY INCREASES TRANSPLANT SURVIVAL IN 1001 RENAL TRANSPLANTS PERFORMED IN THE NORTHWEST REGION OF ENGLANDTransplantation, 1989
- HLA-MATCHING AND PRETRANSPLANT BLOOD TRANSFUSIONS IN CADAVERIC RENAL TRANSPLANTATION—A CHANGING PICTURE WITH CYCLOSPORINThe Lancet, 1986
- INFLUENCE OF DR MATCHING IN CADAVERIC RENAL TRANSPLANTS PERFORMED WITH CYCLOSPORINETransplantation, 1984